Pache.co Information Technologies

Seung KJ, Keshavjee S, Rich ML. 2015. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med 5:a017863.

Berhanu RH, Schnippel K, Kularatne R, Firnhaber C, Jacobson KR, Horsburgh CR, Lippincott CK. 2018. Can patients afford the cost of treatment for multidrug-resistant tuberculosis in ethiopia Int J Tuberc Lung Dis 22:358–362.

Niederweis M, Danilchanka O, Huff J, Hoffmann C, Engelhardt H. 2010. Mycobacterial outer membranes: in search of proteins. Trends Microbiol 18:109–116.

Jarlier V, Nikaido H. 1994. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol Lett 123:11–18.

Cohen KA, Bishai WR, Pym AS. 2014. Molecular basis of drug resistance in Mycobacterium tuberculosis. Microbiol Spectr 2.

Islam MM, Hameed HMA, Mugweru J, Chhotaray C, Wang C, Tan Y, Liu J, Li X, Tan S, Ojima I, Yew WW, Nuermberger E, Lamichhane G, Zhang T. 2017. Drug resistance mechanisms and novel drug targets for tuberculosis therapy. J Genet Genomics 44:21–37.

Remm S, Earp JC, Dick T, Dartois V, Seeger MA. 2022. Critical discussion on drug efflux in Mycobacterium tuberculosis. FEMS Microbiol Rev 46:fuab050.

Milano A, Pasca MR, Provvedi R, Lucarelli AP, Manina G, Ribeiro AL, Manganelli R, Riccardi G. 2009. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. Tuberculosis (Edinb) 89:84–90.

Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A. 2014. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 9:e102135.

Hartkoorn RC, Uplekar S, Cole ST. 2014. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:2979–2981.

Lange C, Chesov D, Heyckendorf J. 2019. Clofazimine for the treatment of multidrug-resistant tuberculosis. Clin Microbiol Infect 25:128–130.

Stadler JAM, Maartens G, Meintjes G, Wasserman S. 2023. Clofazimine for the treatment of tuberculosis. Front Pharmacol 14:1100488.

Yao G, Zhu M, Nie Q, Chen N, Tu S, Zhou Y, Xiao F, Liu Y, Li X, Chen H. 2023. Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis. J Int Med Res 51:3000605221148416.

Pang Y, Zong Z, Huo F, Jing W, Ma Y, Dong L, Li Y, Zhao L, Fu Y, Huang H. 2017. In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China. Antimicrob Agents Chemother 61:e00900-17.

Guo Q, Bi J, Lin Q, Ye T, Wang Z, Wang Z, Liu L, Zhang G. 2022. Whole genome sequencing identifies novel mutations associated with bedaquiline resistance in Mycobacterium tuberculosis. Front Cell Infect Microbiol 12:807095.

Wells RM, Jones CM, Xi Z, Speer A, Danilchanka O, Doornbos KS, Sun P, Wu F, Tian C, Niederweis M. 2013. Discovery of a siderophore export system essential for virulence of Mycobacterium tuberculosis. PLoS Pathog 9:e1003120.

Jones CM, Wells RM, Madduri AVR, Renfrow MB, Ratledge C, Moody DB, Niederweis M. 2014. Self-poisoning of Mycobacterium tuberculosis by interrupting siderophore recycling. Proc Natl Acad Sci U S A 111:1945–1950.

Zhang L, Hendrickson RC, Meikle V, Lefkowitz EJ, Ioerger TR, Niederweis M, Boshoff HI. 2020. Comprehensive analysis of iron utilization by Mycobacterium tuberculosis. PLoS Pathog 16:e1008337.

Zhang L., Kent JE, Whitaker M, Young DC, Herrmann D, Aleshin AE, Ko YH, Cingolani G, Saad JS, Moody DB, Marassi FM, Ehrt S, Niederweis M. 2022. A periplasmic cinched protein is required for siderophore secretion and virulence of Mycobacterium tuberculosis. Nat Commun 13:2255.

Wang Q, Boshoff HIM, Harrison JR, Ray PC, Green SR, Wyatt PG, Barry CE III. 2020. PE/PPE proteins mediate nutrient transport across the outer membrane of Mycobacterium tuberculosis . Science 367:1147–1151.

Lerner TR, Queval CJ, Fearns A, Repnik U, Griffiths G, Gutierrez MG. 2018. Phthiocerol dimycocerosates promote access to the cytosol and intracellular burden of Mycobacterium tuberculosis in lymphatic endothelial cells. BMC Biol 16:1.

Quigley J, Hughitt VK, Velikovsky CA, Mariuzza RA, El-Sayed NM, Briken V, Kaufmann SHE. 2017. The cell wall lipid PDIM contributes to phagosomal escape and host cell exit of Mycobacterium tuberculosis. mBio 8:e00148-17.

Domenech P, Reed MB. 2009. Rapid and spontaneous loss of phthiocerol dimycocerosate (PDIM) from Mycobacterium tuberculosis grown in vitro: implications for virulence studies. Microbiology (Reading) 155:3532–3543.

Kaps I, Ehrt S, Seeber S, Schnappinger D, Martin C, Riley LW, Niederweis M. 2001. Energy transfer between fluorescent proteins using a co-expression system in Mycobacterium smegmatis. Gene 278:115–124.

Villellas C, Coeck N, Meehan CJ, Lounis N, de Jong B, Rigouts L, Andries K. 2017. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. J Antimicrob Chemother 72:684–690.

Saeed DK, Shakoor S, Razzak SA, Hasan Z, Sabzwari SF, Azizullah Z, Kanji A, Nasir A, Shafiq S, Ghanchi NK, Hasan R. 2022. Variants associated with bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naive TB patients in Pakistan. BMC Microbiol 22:62.

Danilchanka O, Mailaender C, Niederweis M. 2008. Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis. Antimicrob Agents Chemother 52:2503–2511.

Nikaido H. 2001. Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. Semin Cell Dev Biol 12:215–223.

Domenech P, Reed MB, Barry CE. 2005. Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun 73:3492–3501.

Viljoen A, Dubois V, Girard-Misguich F, Blaise M, Herrmann JL, Kremer L. 2017. The diverse family of MmpL transporters in mycobacteria: from regulation to antimicrobial developments. Mol Microbiol 104:889–904.

Cortes T, Schubert OT, Rose G, Arnvig KB, Comas I, Aebersold R, Young DB. 2013. Genome-wide mapping of transcriptional start sites defines an extensive leaderless transcriptome in Mycobacterium tuberculosis. Cell Rep 5:1121–1131.

Liu Y, Gao J, Du J, Shu W, Wang L, Wang Y, Xue Z, Li L, Xu S, Pang Y. 2021. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis. Int J Infect Dis 102:392–396.

Nimmo C, Millard J, van Dorp L, Brien K, Moodley S, Wolf A, Grant AD, Padayatchi N, Pym AS, Balloux F, O’Donnell M. 2020. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in Southern Africa: a phenotypic and phylogenetic analysis. Lancet Microbe 1:e165–e174.

Fang Z, Sampson SL, Warren RM, Gey van Pittius NC, Newton-Foot M. 2015. Iron acquisition strategies in mycobacteria. Tuberculosis 95:123–130.

Cynamon MH, Klemens SP, Sharpe CA, Chase S. 1999. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model . Antimicrob Agents Chemother 43:1189–1191.

Escribano I, Rodríguez JC, Llorca B, García-Pachon E, Ruiz M, Royo G. 2007. Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Chemotherapy 53:397–401.

Grzegorzewicz AE, Pham H, Gundi VAKB, Scherman MS, North EJ, Hess T, Jones V, Gruppo V, Born SEM, Korduláková J, Chavadi SS, Morisseau C, Lenaerts AJ, Lee RE, McNeil MR, Jackson M. 2012. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol 8:334–341.

Belardinelli JM, Yazidi A, Yang L, Fabre L, Li W, Jacques B, Angala SK, Rouiller I, Zgurskaya HI, Sygusch J, Jackson M. 2016. Structure-function profile of MmpL3, the essential mycolic acid transporter from Mycobacterium tuberculosis. ACS Infect Dis 2:702–713.

Jain M, Cox JS. 2005. Interaction between polyketide synthase and transporter suggests coupled synthesis and export of virulence lipid in M. tuberculosis. PLoS Pathog 1:e2.

Converse SE, Mougous JD, Leavell MD, Leary JA, Bertozzi CR, Cox JS. 2003. MmpL8 is required for sulfolipid-1 biosynthesis and Mycobacterium tuberculosis virulence. Proc Natl Acad Sci U S A 100:6121–6126.

Pacheco SA, Hsu FF, Powers KM, Purdy GE. 2013. MmpL11 protein transports mycolic acid-containing lipids to the mycobacterial cell wall and contributes to biofilm formation in Mycobacterium smegmatis. J Biol Chem 288:24213–24222.

Belardinelli JM, Larrouy-Maumus G, Jones V, Sorio de Carvalho LP, McNeil MR, Jackson M. 2014. Biosynthesis and translocation of unsulfated acyltrehaloses in Mycobacterium tuberculosis. J Biol Chem 289:27952–27965.

Arnold FM, Weber MS, Gonda I, Gallenito MJ, Adenau S, Egloff P, Zimmermann I, Hutter CAJ, Hürlimann LM, Peters EE, Piel J, Meloni G, Medalia O, Seeger MA. 2020. The ABC exporter IrtAB imports and reduces mycobacterial siderophores. Nature 580:413–417.

Horiyama T, Nishino K. 2014. AcrB, AcrD, and MdtABC multidrug efflux systems are involved in enterobactin export in Escherichia coli. PLoS One 9:e108642.

Vega DE, Young KD. 2014. Accumulation of periplasmic enterobactin impairs the growth and morphology of Escherichia coli tolC mutants. Mol Microbiol 91:508–521.

Bleuel C, Grosse C, Taudte N, Scherer J, Wesenberg D, Krauss GJ, Nies DH, Grass G. 2005. TolC is involved in enterobactin efflux across the outer membrane of Escherichia coli. J Bacteriol 187:6701–6707.

Koch A, Cox H, Mizrahi V. 2018. Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment. Curr Opin Pharmacol 42:7–15.

Ausubel FA, Brent R, Kingston RE, Moore DD, Seidmann JG, Smith JA, Struhl K. 1990. Current protocols in molecular biology. Greene Publishing and Wiley-Interscience, New York.

Smeulders MJ, Keer J, Speight RA, Williams HD. 1999. Adaptation of Mycobacterium smegmatis to stationary phase. J Bacteriol 181:270–283.

Larsen MH, Biermann K, Tandberg S, Hsu T, Jacobs WR. 2007. Genetic manipulation of Mycobacterium tuberculosis. Curr Protoc Microbiol Chapter 10:Unit 10A.2.

Ratledge C, Ewing M. 1996. The occurrence of carboxymycobactin, the siderophore of pathogenic mycobacteria, as a second extracellular siderophore in Mycobacterium smegmatis. Microbiology (Reading) 142 (Pt 8):2207–2212.